Project Grant HT94252510487

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...

This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,289 to Duke University to develop a lipid nanoparticle (LNP) system for delivering the CRISPR/Cas13d gene editing system to target the transcription factor HOXB13 and inhibit prostate cancer metastasis. The award period is from January 1, 2025 to December 31, 2029. The project has two key aims: 1) Uncover the molecular and genomic mechanisms by which HOXB13 activates oncogenic...

This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...